Qing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qing Li has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Chen Meng
Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China; Institute of Anesthesiology, Hubei University of Medicine, Shiyan 442000, Hubei, China
3 shared publicationsDi Yu
Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan, China
2 shared publications- Jing Lv
Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China; Institute of Anesthesiology, Hubei University of Medicine, Shiyan 442000, Hubei, China
2 shared publications Xian-Yu Wang
From the Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China
2 shared publicationsXianyu Wang
Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China; Institute of Anesthesiology, Hubei University of Medicine, Shiyan 442000, Hubei, China
2 shared publicationsYi Liu
Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan, P.R. China
2 shared publications
Latest Publications
- Open Access
- 23 December 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Association between intraoperative blood transfusion and postoperative delirium in elderly patients undergoing total hip arthroplasty with combined spinal-epidural anesthesia: an IPTW-adjusted retrospective cohort study
Perioperative blood transfusion has been considered a potential risk factor for postoperative delirium (POD) in elderly patients. However, the association
- 23 December 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessAssociation between intraoperative blood transfusion and postoperative delirium in elderly patients undergoing total hip arthroplasty with combined spinal-epidural anesthesia: an IPTW-adjusted retrospective cohort study
Perioperative blood transfusion has been considered a potential risk factor for postoperative delirium (POD) in elderly patients. However, the association
- Open Access
- 1 December 2025
- Published by KEAI Publishing in Journal of Anesthesia and Translational Medicine
- Vol. 4 (4) , 234-240
Association between preoperative anemia and postoperative delirium in elderly patients undergoing total hip arthroplasty with combined spinal-epidural anesthesia: A retrospective cohort study
The effect of preoperative anemia on postoperative delirium (POD) risk in elderly patients undergoing total hip arthroplasty (THA) with spinal-epidural anesthesia remains unclear. This study aimed to evaluate the association of preoperative anemia and its severity on POD occurrence in this population. This retrospective cohort study included 609 patients aged ≥ 65 years who underwent their first elective total THA with CSE between January 1, 2020, and December 31, 2024. Patients were stratified by preoperative anemia status using WHO criteria as hemoglobin < 13 g/dL males and < 12 g/dL females. Anemia severity was further stratified into mild or moderate-to-severe categories using a hemoglobin cutoff of 11 g/dL. Inverse probability of treatment weighting (IPTW) was employed to adjust for potential confounders. The primary outcome was the incidence of postoperative delirium. The secondary outcomes included in-hospital deep vein thrombosis, pulmonary infection, surgical site infection, and length of hospital stay (LOS). The overall POD incidence was 4.5 % (24/538). Moderate-to -severe anemia was significantly associated with increased POD risk (odds ratio [OR] 3.29; 95 % confidence interval [CI], 1.21–8.96; P = 0.02). No statistically significant differences were observed for secondary outcomes between groups. Moderate-to-severe preoperative anemia was significantly associated with an increased risk of postoperative delirium in elderly patients undergoing THA with combined spinal-epidural anesthesia. Further prospective studies are warranted to evaluate the efficacy of specific interventions aimed at correcting preoperative anemia in this patient population.
- 1 December 2025
- Published by KEAI Publishing in Journal of Anesthesia and Translational Medicine
- Vol. 4 (4) , 234-240
Open AccessAssociation between preoperative anemia and postoperative delirium in elderly patients undergoing total hip arthroplasty with combined spinal-epidural anesthesia: A retrospective cohort study
The effect of preoperative anemia on postoperative delirium (POD) risk in elderly patients undergoing total hip arthroplasty (THA) with spinal-epidural anesthesia remains unclear. This study aimed to evaluate the association of preoperative anemia and its severity on POD occurrence in this population. This retrospective cohort study included 609 patients aged ≥ 65 years who underwent their first elective total THA with CSE between January 1, 2020, and December 31, 2024. Patients were stratified by preoperative anemia status using WHO criteria as hemoglobin < 13 g/dL males and < 12 g/dL females. Anemia severity was further stratified into mild or moderate-to-severe categories using a hemoglobin cutoff of 11 g/dL. Inverse probability of treatment weighting (IPTW) was employed to adjust for potential confounders. The primary outcome was the incidence of postoperative delirium. The secondary outcomes included in-hospital deep vein thrombosis, pulmonary infection, surgical site infection, and length of hospital stay (LOS). The overall POD incidence was 4.5 % (24/538). Moderate-to -severe anemia was significantly associated with increased POD risk (odds ratio [OR] 3.29; 95 % confidence interval [CI], 1.21–8.96; P = 0.02). No statistically significant differences were observed for secondary outcomes between groups. Moderate-to-severe preoperative anemia was significantly associated with an increased risk of postoperative delirium in elderly patients undergoing THA with combined spinal-epidural anesthesia. Further prospective studies are warranted to evaluate the efficacy of specific interventions aimed at correcting preoperative anemia in this patient population.
- 16 January 2023
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 375, 578021
Ferroptosis participated in hippocampal neuroinflammation damage of in offspring rats after maternal sleep deprivation
- 16 January 2023
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 375, 578021
Ferroptosis participated in hippocampal neuroinflammation damage of in offspring rats after maternal sleep deprivation
- Open Access
- 29 March 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 690272
Tropisetron Preconditioning Decreases Myocardial Biomarkers in Patients Undergoing Heart Valve Replacement Surgery
Background: Cardioplegic arrest during the heart valve replacement surgery frequently leads to myocardial damage. Tropisetron (TRP) has been demonstrated to reduce myocardial ischemia-reperfusion injury and inflammation in animals. We examined the efficacy of TRP in lowering myocardial biomarkers in patients undergoing heart valve replacement surgery.Methods: A total of seventy-five patients, scheduled for elective heart valve replacement surgery, were randomly chosen to receive either 10 ml of normal saline or 10 mg/10 ml of TRP immediately after anesthesia induction. Blood samples for the measurement of cardiac troponin I (cTnI), creatine kinase (CK-MB), lactate dehydrogenase (LDH), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-10 (IL-10) were taken before anesthesia, as well as 4, 12, and 24 h after aortic cross-clamp release to evaluate myocardial injury using two-way ANOVA for repeated measurements. The study was registered at www.chictr.org.cn (number, ChiCTR-1800018681).Results: Treatment with TRP decreased the increment of cTnI (Fgroup = 4.911, p = 0.030; Ftime = 55.356, p = 0.001; Fgroup × time = 5.340, p = 0.002) at 12 and 24 h; of CK-MB (Fgroup = 6.552, p = 0.013; Ftime = 49.276, p = 0.001; Fgroup × time = 7.627, p = 0.003) at 4, 12, and 24 h; of TNF-α (Fgroup = 4.153, p = 0.046; Ftime = 28.244, p = 0.002; Fgroup × time = 4.692, p = 0.006) at 4 and 12 h; and of LDH (Fgroup = 4.275, p = 0.043; Ftime = 63.225, p = 0.001; Fgroup × time = 2.501, p = 0.083) at 24 h after the release of the aortic cross-clamp. It increased IL-10 (Fgroup = 5.958, p = 0.018; Ftime = 31.226, p = 0.002; Fgroup × time = 1.464, p = 0.236) at 12 h after the release of the aortic cross-clamp. Multiple linear regression analysis showed that cardiopulmonary bypass (CPB) time was a risk factor, and that TRP treatment was a protective factor for postoperative cTNI change (β = 4.449, 95% CI [0.97–7.92], p = 0.013 for CPB time; and β = −381, 95% CI [−613.4 to −148.5], p = 0.002 for TRP treatment).Conclusions: Tropisetron had cardioprotective and anti-inflammatory effects in patients undergoing heart valve replacement surgery with cardioplegic arrest. The addition of TRP and reduction of CPB time should be considered for myocardial protection in heart valve replacement surgery.Clinical Trial Registration: [www.chictr.org.cn/index.aspx], identifier [ChiCTR1800018681].
- 29 March 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 690272
Open AccessTropisetron Preconditioning Decreases Myocardial Biomarkers in Patients Undergoing Heart Valve Replacement Surgery
Background: Cardioplegic arrest during the heart valve replacement surgery frequently leads to myocardial damage. Tropisetron (TRP) has been demonstrated to reduce myocardial ischemia-reperfusion injury and inflammation in animals. We examined the efficacy of TRP in lowering myocardial biomarkers in patients undergoing heart valve replacement surgery.Methods: A total of seventy-five patients, scheduled for elective heart valve replacement surgery, were randomly chosen to receive either 10 ml of normal saline or 10 mg/10 ml of TRP immediately after anesthesia induction. Blood samples for the measurement of cardiac troponin I (cTnI), creatine kinase (CK-MB), lactate dehydrogenase (LDH), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-10 (IL-10) were taken before anesthesia, as well as 4, 12, and 24 h after aortic cross-clamp release to evaluate myocardial injury using two-way ANOVA for repeated measurements. The study was registered at www.chictr.org.cn (number, ChiCTR-1800018681).Results: Treatment with TRP decreased the increment of cTnI (Fgroup = 4.911, p = 0.030; Ftime = 55.356, p = 0.001; Fgroup × time = 5.340, p = 0.002) at 12 and 24 h; of CK-MB (Fgroup = 6.552, p = 0.013; Ftime = 49.276, p = 0.001; Fgroup × time = 7.627, p = 0.003) at 4, 12, and 24 h; of TNF-α (Fgroup = 4.153, p = 0.046; Ftime = 28.244, p = 0.002; Fgroup × time = 4.692, p = 0.006) at 4 and 12 h; and of LDH (Fgroup = 4.275, p = 0.043; Ftime = 63.225, p = 0.001; Fgroup × time = 2.501, p = 0.083) at 24 h after the release of the aortic cross-clamp. It increased IL-10 (Fgroup = 5.958, p = 0.018; Ftime = 31.226, p = 0.002; Fgroup × time = 1.464, p = 0.236) at 12 h after the release of the aortic cross-clamp. Multiple linear regression analysis showed that cardiopulmonary bypass (CPB) time was a risk factor, and that TRP treatment was a protective factor for postoperative cTNI change (β = 4.449, 95% CI [0.97–7.92], p = 0.013 for CPB time; and β = −381, 95% CI [−613.4 to −148.5], p = 0.002 for TRP treatment).Conclusions: Tropisetron had cardioprotective and anti-inflammatory effects in patients undergoing heart valve replacement surgery with cardioplegic arrest. The addition of TRP and reduction of CPB time should be considered for myocardial protection in heart valve replacement surgery.Clinical Trial Registration: [www.chictr.org.cn/index.aspx], identifier [ChiCTR1800018681].
- 3 March 2022
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- Vol. 47 (2) , 277-285
Tropisetron attenuates neuroinflammation and chronic neuropathic pain via α7nAChR activation in the spinal cord in rats
Tropisetron is an alpha 7 nicotinic acetylcholine receptor (α7nAChR) agonist and is a commonly used antiemetic clinically. α7nAChRs activation modulating nociception transmissions and cholinergic a...
- 3 March 2022
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- Vol. 47 (2) , 277-285
Tropisetron attenuates neuroinflammation and chronic neuropathic pain via α7nAChR activation in the spinal cord in rats
Tropisetron is an alpha 7 nicotinic acetylcholine receptor (α7nAChR) agonist and is a commonly used antiemetic clinically. α7nAChRs activation modulating nociception transmissions and cholinergic a...
- Open Access
- 1 May 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 125, 109995
Amphiregulin inhibits TNF-α-induced alveolar epithelial cell death through EGFR signaling pathway
- 1 May 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 125, 109995
Open AccessAmphiregulin inhibits TNF-α-induced alveolar epithelial cell death through EGFR signaling pathway
- 1 February 2020
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 130 (2) , 505-517
Exogenous GM1 Ganglioside Attenuates Ketamine-Induced Neurocognitive Impairment in the Developing Rat Brain
BACKGROUND: A prolonged exposure to ketamine triggers significant neurodegeneration and long-term neurocognitive deficits in the developing brain. Monosialotetrahexosylganglioside (GM1) can limit the neuronal damage from necrosis and apoptosis in neurodegenerative conditions. We aimed to assess whether GM1 can prevent ketamine-induced developmental neurotoxicity. METHODS: Postnatal day 7 (P7) rat pups received 5 doses of intraperitoneal ketamine (20 mg/kg per dose) at 90-minute intervals for 6 hours. Cognitive functions, determined by using Morris water maze (MWM) including escape latency (at P32–36) and platform crossing (at P37), were compared among the ketamine-exposed pups treated with or without exogenous GM1 (30 mg/kg; n = 12/group). The effect of GM1 on apoptosis in hippocampus was determined by terminal deoxynucleotidyl transferase–mediated 2′-deoxyuridine 5′-triphosphate nick end labeling (TUNEL) staining and activated caspase 3 measurement. The hippocampal expression of brain-derived neurotrophic factor (BDNF), along with the phosphorylation of protein kinase B (AKT) and extracellular signal-related kinases 1 and 2 (ERK1/2), was detected by western blotting (n = 6/group). Anti-BDNF antibody (2 μg per rat) administered before GM1 treatment was applied to determine the neuroprotective mechanisms of GM1. RESULTS: The rats receiving ketamine exposure experinced cognitive impairment in MWM test compared to the control rats, indicated by prolonged escape latency at P34 (P = .006), P35 (P = .002), and P36 (P = .005). However, in GM1-pretreated rats, ketamine exposure did not induce prolonged escape latency. The exogenous GM1 increased the platform-crossing times at P37 (3.00 ± 2.22 times vs 5.40 ± 1.53 times, mean ± standard deviation; P = .041) and reduced the hippocampal TUNEL-positive cells and cleaved-caspase 3 expression in ketamine-exposed young rats. Ketamine decreased BDNF expression and phosphorylation of AKT and ERK in the hippocampus, whereas exogenous GM1 blocked these ketamine-caused effects. However, for the ketamine-exposed rat pups receiving exogenous GM1, compared to immunoglobulin Y (IgY) isotype control, the BDNF-neutralizing antibody treatment counteracted the exogenous GM1-induced improvement of the escape latency at P36 (41.32 ± 12.37 seconds vs 25.14 ± 8.97 seconds, mean ± standard deviation; P = .036), platform-crossing times at P37 (2.16 ± 1.12 times vs 3.92 ± 1.97 times, mean ± standard deviation; P < .036), apoptotic activity, as well as AKT and ERK1/2 phosphorylation in the hippocampus of ketamine-challenged young rats. CONCLUSIONS: Our data suggest that the exogenous GM1 acts on BDNF signaling pathway to ameliorate the cognitive impairment and hippocampal apoptosis induced by ketamine in young rats. Our study may indicate a potential use of GM1 in preventing the cognitive deficits induced by ketamine in the young per se.
- 1 February 2020
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 130 (2) , 505-517
Exogenous GM1 Ganglioside Attenuates Ketamine-Induced Neurocognitive Impairment in the Developing Rat Brain
BACKGROUND: A prolonged exposure to ketamine triggers significant neurodegeneration and long-term neurocognitive deficits in the developing brain. Monosialotetrahexosylganglioside (GM1) can limit the neuronal damage from necrosis and apoptosis in neurodegenerative conditions. We aimed to assess whether GM1 can prevent ketamine-induced developmental neurotoxicity. METHODS: Postnatal day 7 (P7) rat pups received 5 doses of intraperitoneal ketamine (20 mg/kg per dose) at 90-minute intervals for 6 hours. Cognitive functions, determined by using Morris water maze (MWM) including escape latency (at P32–36) and platform crossing (at P37), were compared among the ketamine-exposed pups treated with or without exogenous GM1 (30 mg/kg; n = 12/group). The effect of GM1 on apoptosis in hippocampus was determined by terminal deoxynucleotidyl transferase–mediated 2′-deoxyuridine 5′-triphosphate nick end labeling (TUNEL) staining and activated caspase 3 measurement. The hippocampal expression of brain-derived neurotrophic factor (BDNF), along with the phosphorylation of protein kinase B (AKT) and extracellular signal-related kinases 1 and 2 (ERK1/2), was detected by western blotting (n = 6/group). Anti-BDNF antibody (2 μg per rat) administered before GM1 treatment was applied to determine the neuroprotective mechanisms of GM1. RESULTS: The rats receiving ketamine exposure experinced cognitive impairment in MWM test compared to the control rats, indicated by prolonged escape latency at P34 (P = .006), P35 (P = .002), and P36 (P = .005). However, in GM1-pretreated rats, ketamine exposure did not induce prolonged escape latency. The exogenous GM1 increased the platform-crossing times at P37 (3.00 ± 2.22 times vs 5.40 ± 1.53 times, mean ± standard deviation; P = .041) and reduced the hippocampal TUNEL-positive cells and cleaved-caspase 3 expression in ketamine-exposed young rats. Ketamine decreased BDNF expression and phosphorylation of AKT and ERK in the hippocampus, whereas exogenous GM1 blocked these ketamine-caused effects. However, for the ketamine-exposed rat pups receiving exogenous GM1, compared to immunoglobulin Y (IgY) isotype control, the BDNF-neutralizing antibody treatment counteracted the exogenous GM1-induced improvement of the escape latency at P36 (41.32 ± 12.37 seconds vs 25.14 ± 8.97 seconds, mean ± standard deviation; P = .036), platform-crossing times at P37 (2.16 ± 1.12 times vs 3.92 ± 1.97 times, mean ± standard deviation; P < .036), apoptotic activity, as well as AKT and ERK1/2 phosphorylation in the hippocampus of ketamine-challenged young rats. CONCLUSIONS: Our data suggest that the exogenous GM1 acts on BDNF signaling pathway to ameliorate the cognitive impairment and hippocampal apoptosis induced by ketamine in young rats. Our study may indicate a potential use of GM1 in preventing the cognitive deficits induced by ketamine in the young per se.
- Open Access
- 15 November 2014
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 9 (22) , 2002-2007
Propofol and remifentanil at moderate and high concentrations affect proliferation and differentiation of neural stem/progenitor cells
Propofol and remifentanil alter intracellular Ca 2+ concentration ([Ca 2+ ] i ) in neural stem/progenitor cells by activating γ-aminobutyric acid type A receptors and by reducing testosterone levels. However, whether this process affects neural stem/progenitor cell proliferation and differentiation remains unknown. In the present study, we applied propofol and remifentanil, alone or in combination, at low, moderate or high concentrations (1, 2–2.5 and 4–5 times the clinically effective blood drug concentration), to neural stem/progenitor cells from the hippocampi of newborn rat pups. Low concentrations of propofol, remifentanil or both had no noticeable effect on cell proliferation or differentiation; however, moderate and high concentrations of propofol and/or remifentanil markedly suppressed neural stem/progenitor cell proliferation and differentiation, and induced a decrease in [Ca 2+ ] i during the initial stage of neural stem/progenitor cell differentiation. We therefore propose that propofol and remifentanil interfere with the proliferation and differentiation of neural stem/progenitor cells by altering [Ca 2+ ] i . Our findings suggest that propofol and/or remifentanil should be used with caution in pediatric anesthesia.
- 15 November 2014
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 9 (22) , 2002-2007
Open AccessPropofol and remifentanil at moderate and high concentrations affect proliferation and differentiation of neural stem/progenitor cells
Propofol and remifentanil alter intracellular Ca 2+ concentration ([Ca 2+ ] i ) in neural stem/progenitor cells by activating γ-aminobutyric acid type A receptors and by reducing testosterone levels. However, whether this process affects neural stem/progenitor cell proliferation and differentiation remains unknown. In the present study, we applied propofol and remifentanil, alone or in combination, at low, moderate or high concentrations (1, 2–2.5 and 4–5 times the clinically effective blood drug concentration), to neural stem/progenitor cells from the hippocampi of newborn rat pups. Low concentrations of propofol, remifentanil or both had no noticeable effect on cell proliferation or differentiation; however, moderate and high concentrations of propofol and/or remifentanil markedly suppressed neural stem/progenitor cell proliferation and differentiation, and induced a decrease in [Ca 2+ ] i during the initial stage of neural stem/progenitor cell differentiation. We therefore propose that propofol and remifentanil interfere with the proliferation and differentiation of neural stem/progenitor cells by altering [Ca 2+ ] i . Our findings suggest that propofol and/or remifentanil should be used with caution in pediatric anesthesia.
- Open Access
- 25 August 2010
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section E Crystallographic Communications
- Vol. 66 (9) , o2384
Ethyl 2-isopropylamino-6-methyl-8-oxo-3-phenyl-3H,8H-furo[2,3-d][1,2,4]triazolo[1,5-a]pyrimidine-7-carboxylate
In the title compound, C(20)H(21)N(5)O(4), the ring system containing the three fused rings is essentially planar (r.m.s. deviation for all 12 non-H atoms = 0.041 Å). The phenyl ring makes a dihedral angle of 54.41 (6)° with this ring system. The isopropyl group is disordered over two positions, with site-occupancy factors of 0.753 (9) and 0.247 (9). The structure is mainly stabilized by weak inter-molecular N-H⋯O and intra-molecular C-H⋯O hydrogen-bonding inter-actions and π-π inter-actions, with inter-planar distances of 3.415 (1) Å between adjacent furan ring centroids and 3.420 (1) Å between the benzene and pyrimidinone rings.
- 25 August 2010
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section E Crystallographic Communications
- Vol. 66 (9) , o2384
Open AccessEthyl 2-isopropylamino-6-methyl-8-oxo-3-phenyl-3H,8H-furo[2,3-d][1,2,4]triazolo[1,5-a]pyrimidine-7-carboxylate
In the title compound, C(20)H(21)N(5)O(4), the ring system containing the three fused rings is essentially planar (r.m.s. deviation for all 12 non-H atoms = 0.041 Å). The phenyl ring makes a dihedral angle of 54.41 (6)° with this ring system. The isopropyl group is disordered over two positions, with site-occupancy factors of 0.753 (9) and 0.247 (9). The structure is mainly stabilized by weak inter-molecular N-H⋯O and intra-molecular C-H⋯O hydrogen-bonding inter-actions and π-π inter-actions, with inter-planar distances of 3.415 (1) Å between adjacent furan ring centroids and 3.420 (1) Å between the benzene and pyrimidinone rings.